Anticancer agent 312 

Anticancer agent 312 is a heterogeneous nuclear ribonucleoprotein A18 (hnRNP A18) inhibitor with an IC₅₀ of 2.9 μM. Anticancer agent 312 binds to the RNA recognition motif of hnRNP A18 and blocks its binding to homologous RNA transcripts. Anticancer agent 312 acts as a protein synthesis inhibitor by blocking hnRNP A18-mediated mRNA translation. Anticancer agent 312 is applicable to research on cancers such as melanoma^[1].

Anticancer agent 312 (Compound 5) (3 h) binds to and stabilizes hnRNP A18 in LOX-IM-VI melanoma cells, with an EC₅₀ of 23.8 μM^[1].
Anticancer agent 312 disrupts hnRNP A18-mediated transcript stability and translation in LOX-IM-VI melanoma cells, and reduces the expression of CAT protein carrying the Trx 3'UTR reporter gene^[1].
Anticancer agent 312 (0-200 μM) downregulates the protein expression of thioredoxin in LOX-IM-VI melanoma cells in a dose-dependent manner^[1].
Anticancer agent 312 (0-200 μM) downregulates CTLA-4 protein expression in PC-3 prostate cancer cells in a dose-dependent manner^[1].
Anticancer agent 312 (0-150 μM; 24 h) selectively reduces the viability of various human cancer cell lines, and exhibits moderate toxicity to normal human mammary epithelial cells at high concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

338.38

C₁₈H₁₄N₂O₃S

664968-32-5

O=C(C1=CC=CC=C1)OC2=C(C)SC(NC(C3=CC=CC=C3)=O)=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. France Carrier, et al. Protein Translation Inhibitors and Uses Thereof. US20200368208A1.